2020-21 Colorectal cancer - Extended MMR

Scheme description
Molecular testing of colorectal cancer. KRAS, NRAS, BRAF, MSI and MLH1 promoter methylation testing.
Disorders/Gene target(s)
Colorectal cancer,
KRAS
NRAS
BRAF
MLH1 promoter methylation
Microsatellite instability (MSI)
Mismatch repair
Clinical cases
Five cases for round 1, Four cases for round 2
Testing/analysis
Any
Sample type
Formalin fixed paraffin embedded sections supplied as
1) rolled sections,
2) slide mounted sections
or 3) rolled sections plus one slide mounted section for H&E staining.
Please indicate your sample choice when enrolling.
Techniques
Any molecular testing methods.
Assessment
Submit a clinical report to include:
• Genotyping of results
• Interpretation of the result
• Clerical accuracy
Performance criteria are applied.
Eligibility
All laboratories worldwide
Languages
English ONLY
ISO1743 Accredited EQA
Yes
EQA timeline
Sample dispatchApril 2020 <br>October 2020
Testing period6 weeks
Assessment resultsAugust 2020 <br>February 2021
Final Summary reportOctober 2020 <br>April 2021
Other information
Two distributions per year
Fee
£800.00
GenQA code
2020CRCMSI1
« Return to EQA scheme list
Go to top